Bruker Corporation ("Bruker" or the "Company") (NASDAQ:BRKR) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the
Financial Outlook"During the first quarter we saw increased deal scrutiny and lengthening sales cycles for large multi-year deals. We have considered these factors, the current macroeconomic environment and our
UiPath reported quarterly earnings of 13 cents per share which beat the analyst consensus estimate of 12 cents by 8.33%.
Quarterly sales came in at $335 million which beat the analyst consensus estimate of $333.04 million and represents a 15.68% increase over sales of $289.59 million from the same period last year.
Cryptocurrency markets traded within a tight downward range on Wednesday, as traditional markets had a rocky trading day with increased volatility.
Prices as of 4:00 p.m. ET:
In the study, patients with DecisionDx-SCC Class 2B test results, predicted to have the highest risk of metastasis by the test, who were treated with adjuvant radiation therapy (ART) had 50% higher metastasis-free survival (MFS) rates, on average, and slowed disease progression compared to Class 2B patients who did not receive ART